Navigation Links
Vasogen Announces 2007 Year-End Results
Date:1/16/2008

journal. As

previously reported by Vasogen, while the trial did not meet its

primary endpoint, a key finding from the ACCLAIM trial was a

39% reduction in the risk of death or cardiovascular hospitalizations

for a large pre-specified subgroup of patients with NYHA Class II

heart failure who received Celacade therapy, compared to patients

receiving placebo.

- We entered into a collaboration with Grupo Ferrer Internacional,

S.A., a leading European pharmaceutical and medical devices company,

to commercialize Celacade for the treatment of chronic heart failure

in specified countries of the European Union and in certain Latin

American countries. In December 2007, Ferrer received initial orders

for Celacade in Germany.

- The Food and Drug Administration strongly recommended that we conduct

a confirmatory study (ACCLAIM-II) in NYHA Class II heart failure

patients to support a Pre-market Approval filing for Celacade in the

United States. The FDA also recommended that we utilize a Bayesian

statistical approach for designing the confirmatory trial as it would

allow for the borrowing of statistical power from the ACCLAIM study.

This approach has the potential to substantially reduce the number of

patients required for a confirmatory study, as well as the cost and

duration.

- James B. Young, MD, Chairman, Division of Medicine at the Cleveland

Clinic Foundation and Medical Director, Kaufman Center for Heart

Failure, was appointed the Global Principal Investigator and Chairman

of the Steering Committee for ACCLAIM-II.

- Chris Waddick, MBA, CMA, was appointed President, CEO, and a Member

of the Board of Directors of our Company. Mr. Waddick has held a

series of progressive senior management positions at Vasog
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
(Date:12/19/2014)... Decision Resources Group finds that the Latin ... percent compound annual growth rate through 2023. This is ... the increasing adoption of dental implants. Growing aesthetic consciousness ... spur demand for dental biomaterials because they can improve ... Other key findings from Decision Resources Group,s ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... in Exchange, for Senior Subordinated and Subordinated Notes due 2008, ... ... Feb. 13 Cell Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq: CTIC ... its outstanding 5.75%,Convertible Senior Subordinated Notes due 2008 (the "Senior Subordinated,Notes") and ...
... Recover Investments in Dedicated Assets -, LIONVILLE, ... WST ) today announced that it has ... the manufacture and,assembly of components for the Exubera(R) ... in October 2007 following Pfizer,Inc.,s decision to discontinue ...
... Feb. 13 Verenium,Corporation (Nasdaq: VRNM ), ... pioneer in the development of high-performance specialty,enzymes, announced ... President and Chief Financial Officer, will present at ... The presentation is,scheduled to begin at 10:00 a.m. ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008 2West Concludes Agreement with Nektar 2Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference 2Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference 3
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... places in Asia, Africa, South and Central America and the ... and longer legs, better suited for their habitat. They have ... them to better climb different surfaces, while their light build ... Amazon, from where most of the species are known and ...
... National Physical Laboratory (NPL), along with partners In2Tec Ltd (UK) ... board (PCB) whose components can be easily separated by immersion ... project, funded by the UK government,s Technology Strategy Board. ... waste problem - currently over 100 million electronic units are ...
... date of children with early and later manifestation of ... researchers found two distinct patterns of language, social and ... the journal Child Development , the study found ... of ASD show greater initial delay across multiple aspects ...
Cached Biology News:9 colorful and endangered tree-dwelling tarantulas discovered in Brazil 2Distinct developmental patterns identified in children with autism during their first 3 years 2Distinct developmental patterns identified in children with autism during their first 3 years 3
Criterion staining and blotting trays are plastic trays designed for staining one or two Criterion gels or performing western blot detection. The trays have a working capacity of up to 500 ml. Suppli...
... a wide range of next-generation features into ... new standard for flexible laboratory solutions. It ... including pipetting, dilution, dispensing, and integrations ... powerful and flexible as it is efficient ...
... The Biomek FX P is the latest ... design for greater positional accuracy and increased robustness, ... any application. It can be configured with either ... deck capacity, the Biomek FX P sets ...
BD Falcon, microtest ELISA plate 96 well flat-bottom, clear. Polystyrene, nonsterile, no lid (25/sp, 100/ca) Packaging: 25 / pack, 100 / case ...
Biology Products: